Edward Felix
Overview
Explore the profile of Edward Felix including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
19
Citations
985
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Yamasaki F, Johansen M, Zhang D, Krishnamurthy S, Felix E, Bartholomeusz C, et al.
Cancer Res
. 2007 Jun;
67(12):5779-88.
PMID: 17575145
Erlotinib (Tarceva), an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, has clinical activity in advanced lung cancer, but disease that initially responds to erlotinib eventually progresses. The mechanism of...
12.
Yang P, Chan D, Felix E, Madden T, Klein R, Shureiqi I, et al.
Prostaglandins Leukot Essent Fatty Acids
. 2006 Oct;
75(6):385-95.
PMID: 17011176
Cyclooxygenase and lipoxygenase arachidonate products, including prostaglandins (PGs), leukotrienes (LTs), and hydroxyeicosatetraenoic acids (HETEs), are known to modulate inflammation within tissues and can serve as important etiologic factors in carcinogenesis....
13.
Thaker P, Han L, Kamat A, Arevalo J, Takahashi R, Lu C, et al.
Nat Med
. 2006 Jul;
12(8):939-44.
PMID: 16862152
Stress can alter immunological, neurochemical and endocrinological functions, but its role in cancer progression is not well understood. Here, we show that chronic behavioral stress results in higher levels of...
14.
Morrison D, Thai H, Goldman S, Felix E, Hernandez J
Catheter Cardiovasc Interv
. 2006 Mar;
67(4):571-9.
PMID: 16547927
We hypothesized that the use of stents and aggressive adjunctive pharmacotherapies has been associated with lower rates of complicating myocardial infarction (MI) and improved long-term outcomes compared to either previous...
15.
Newman R, Yang P, Hittelman W, Lu T, Ho D, Ni D, et al.
J Exp Ther Oncol
. 2006 Mar;
5(3):167-81.
PMID: 16528968
While certain cardiac glycoside compounds such as oleandrin, bufalin and digitoxin are known to be associated with potent cytotoxicity to human tumor cells, the mechanisms by which this effect is...
16.
Yang P, Chan D, Felix E, Cartwright C, Menter D, Madden T, et al.
J Lipid Res
. 2004 Mar;
45(6):1030-9.
PMID: 14993240
We investigated the formation and pharmacology of prostaglandin E(3) (PGE(3)) derived from fish oil eicosapentaenoic acid (EPA) in human lung cancer A549 cells. Exposure of A549 cells to EPA resulted...
17.
Ni D, Ho D, Vijjeswarapu M, Felix E, Rhea P, Newman R
J Exp Ther Oncol
. 2003 May;
3(1):47-52.
PMID: 12724858
Homoharringtonine (HHT), first isolated from the Chinese evergreen Cephalotaxus harringtonia, has been demonstrated to have a broad antitumor activity in rodents and antileukemic effects in humans. We found that HHT...
18.
Ni D, Madden T, Johansen M, Felix E, Ho D, Newman R
J Exp Ther Oncol
. 2002 Nov;
2(5):278-85.
PMID: 12416031
Pharmacokinetic studies of [3H]oleandrin, a cardiac glycoside component of Anvirzel, were conducted in mice after either an i.v. dose (40 micrograms/kg) or a p.o. dose (80 micrograms/kg). Oleandrin was rapidly...
19.
Yang P, Felix E, Madden T, Fischer S, Newman R
Anal Biochem
. 2002 Sep;
308(1):168-77.
PMID: 12234478
This paper describes a rapid and simple technique for the simultaneous quantitative analysis of PGE(2), PGE(3), and other closely related prostaglandins from cultured cells using liquid chromatography/electrospray ionization tandem mass...